This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Salmeterol

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Salmeterol is a long-acting beta-2 agonist which is used in the treatment of asthma as an adjunct to inhaled corticosteroids.

The long-lasting action of salmeterol means that it may be taken regularly, twice per day; it is not effective for the relief of an acute asthma attack.

Notes:

  • clinicians should continue to be aware of the possible risks associated with the long-term use of long-acting beta2 agonists (LABAs, i.e. salmeterol and formoterol)
    • should be used only in conjunction with inhaled corticosteroids
  • for the management of chronic asthma, LABAs should:
    • be added only if regular use of standard-dose inhaled corticosteroids has failed to control asthma adequately;
    • not be initiated in patients with rapidly deteriorating asthma;
    • be introduced at a low dose and the effect properly monitored before considering dose increase;
    • be discontinued in the absence of benefit;
    • be reviewed as clinically appropriate: stepping down therapy should be considered when good long-term asthma control has been achieved

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.